12:00 AM
 | 
Feb 06, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Prevacid lansoprazole: Phase IV data

The double-blind, U.S. Phase IV SARCA trial in 306 patients aged 6-17 with poorly controlled asthma who were receiving inhaled corticosteroids (ICS) showed that once-daily oral lansoprazole missed the primary endpoint of significantly reducing ACQ scores from baseline to week 24 vs. placebo...

Read the full 195 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >